

### STATISTICAL COMPENDIUM: MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT IN 2005 **TEXAS**

#### LIST OF TABLES

#### OVERVIEW OF STUDY POPULATION

TABLE 1. OVERVIEW OF BENEFICIARY SELECTION CRITERIA FOR STUDY POPULATION

### FOR ALL MEDICAID BENEFICIARIES

- TABLE 2. CHARACTERISTICS OF MEDICAID STUDY POPULATION BENEFICIARIES, BY BASIS OF ELIGIBILITY
- TABLE 3. ANNUAL MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFICIARY, BY BENEFICIARY CHARACTERISTIC
- TABLE 4. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC
- TABLE 5. AVERAGE MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH. BY BRAND STATUS AND BENEFICIARY CHARACTERISTIC
- TABLE 6. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY BRAND STATUS AND THERAPEUTIC CATEGORY
- TABLE 7. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY TOP 10 DRUG GROUP

#### FOR ALL NONDUAL BENEFICIARIES

- TABLE ND.2. CHARACTERISTICS OF MEDICAID STUDY POPULATION BENEFICIARIES. BY BASIS OF ELIGIBILITY
- TABLE ND.3. ANNUAL MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFICIARY, BY BENEFICIARY CHARACTERISTIC
- TABLE ND.4. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC
- TABLE ND.5. AVERAGE MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BRAND STATUS AND
- BENEFICIARY CHARACTERISTIC
- TABLE ND.6. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY BRAND STATUS AND THERAPEUTIC CATEGORY
- TABLE ND.7-7D. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT. BY TOP 10 DRUG GROUP
- TABLE ND.8. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS, BY BENEFICIARY CHARACTERISTIC
- TABLE ND.9. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS, BY BRAND STATUS AND
- THERAPEUTIC CATEGORY
- TABLE ND.10-10D. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR TOP 10 DRUG GROUPS AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY TOP 10 DRUG GROUP
- TABLE ND.11. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D AMONG NONDUALS, BY
- BENEFICIARY CHARACTERISTIC TABLE ND.12. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D AMONG NONDUALS PER BENEFIT MONTH,
- BY BENEFICIARY CHARACTERISTIC
- TABLE ND.13. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D FOR SELECTED DRUG CATEGORIES
- AMONG NONDUALS

### FOR DUAL ELIGIBLE BENEFICIARIES

- TABLE D.2. CHARACTERISTICS OF MEDICAID STUDY POPULATION BENEFICIARIES, BY BASIS OF ELIGIBILITY
- TABLE D.3. ANNUAL MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFICIARY, BY BENEFICIARY CHARACTERISTIC
- TABLE D.4. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC
- TABLE D.5. AVERAGE MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH. BY BRAND STATUS AND BENEFICIARY CHARACTERISTIC
- TABLE D.6. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY BRAND STATUS AND THERAPEUTIC CATEGORY
- TABLE D.7-7D. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY TOP 10 DRUG GROUP
- TABLE D.8. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS. BY BENEFICIARY CHARACTERISTIC
- TABLE D.9. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS. BY BRAND STATUS AND
- THERAPEUTIC CATEGORY
- TABLE D.10-10D. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR TOP 10 DRUG GROUPS AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY TOP 10 DRUG GROUP
- TABLE D.11. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D AMONG DUALS. BY BENEFICIARY CHARACTERISTIC
- TABLE D.12, USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D AMONG DUALS PER BENEFIT MONTH, BY
- BENEFICIARY CHARACTERISTIC
- TABLE D.13. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D FOR SELECTED DRUG CATEGORIES AMONG DUALS

### SUPPLEMENTAL TABLES

- SUPPLEMENTAL TABLE 1. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES
- SUPPLEMENTAL TABLE 1A. MEDICAID PHARMACY REIMBURSEMENT FOR DISABLED DUAL ELIGIBLE BENEFICIARIES UNDER AGE 65
- SUPPLEMENTAL TABLE 1B. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 65 AND OLDER
- SUPPLEMENTAL TABLE 1C. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 65 TO 74
- SUPPLEMENTAL TABLE 1D. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 75 TO 84
- SUPPLEMENTAL TABLE 1E. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 85 AND OLDER

APPENDIX TABLE A.1. CHARACTERISTICS OF MEDICAID BENEFICIARIES WITH AT LEAST ONE MONTH OF PHARMACY BENEFIT COVERAGE, BY BASIS OF ELIGIBILITY, NONDUAL BENEFICIARIES

APPENDIX TABLE A.2. MEDICAID BENEFICIARIES AND THEIR BENEFIT MONTHS WITH OR WITHOUT FEE-FOR-SERVICE PHARMACY BENEFITS, NONDUAL BENEFICIARIES

APPENDIX TABLE A.3. CHARACTERISTICS OF MEDICAID BENEFICIARIES WITH AT LEAST ONE MONTH OF PHARMACY BENEFIT COVERAGE, BY BASIS OF ELIGIBILITY, DUAL ELIGIBLE BENEFICIARIES

APPENDIX TABLE A.4. MEDICAID BENEFICIARIES AND THEIR BENEFIT MONTHS WITH OR WITHOUT FEE-FOR-SERVICE PHARMACY BENEFITS, DUAL

ELIGIBLE BENEFICIARIES

TABLE ND.2 CHARACTERISTICS OF MEDICAID STUDY POPULATION BENEFICIARIES, BY BASIS OF ELIGIBILITY  $^{a,\ b}$ NONDUAL BENEFICIARIES, TEXAS, 2005

			Number of		BENEFICIAR ies	ILO, TEXAO	, 2003		Number of E	Benefit Month	ns	
Beneficiary Characteristics	All	Aged	Disabled	Adults	Children	Other/ Unknown	All	Aged	Disabled	Adults	Children	Other/ Unknown
All	3,253,138	6.097	317,269		2,464,995	545	23,839,465	57,485		2,366,128	18,242,420	3,733
Age	.,,	-,	,	, ,	, . ,		.,,	,	-,,	,,	-, , -	.,
5 and younger	1,208,235	1	20,176	8	1,188,050	0	8,896,395	4	197,651	23	8,698,717	0
6-14	1,016,455	0	52,888	333	963,234	0	7,847,523	0	558,581	1,626	7,287,316	0
15-20	424,543	0	33,743	77,211	313,587	2	2,990,832	0	351,013	384,068	2,255,739	12
21-44	445,003	5	87,850	356,723	111	314	2,687,799	42	877,851	1,807,240	603	2,063
45-64	152,412	45	122,249	29,883	11	224	1,357,366	282	1,182,804	172,614	42	1,624
65-74	2,921	2,545	308	63	0	5	25,741	23,689	1,522	496	0	34
75-84	2,105	2,059	38	8	0	0	20,202	19,979	180	43	0	0
85 and older	1,462	1,442	17	3	0	0	13,604	13,489	97	18	0	0
Unknown	2	0	0	0	2	0	3	0	0	0	3	0
Gender												
Female	1,799,707	3,845	157,484	422,273	1,215,560	545	12,788,819	36,334	1,590,305	2,149,390	9,009,057	3,733
Male	1,453,371	2,246	159,782	41,957	1,249,386	0	11,050,314	21,084	1,579,388	216,734	9,233,108	0
Unknown	60	6	3	2	49	0	332	67	6	4	255	0
Race												
White	745,226	2,021	97,727	136,040	509,158	280	5,432,441	18,972	984,989	704,457	3,722,114	1,909
African American	622,725	1,222	84,626	108,783	428,009	85	4,205,557	11,299	812,969	501,866	2,878,823	600
Other/unknown	1,885,187	2,854	134,916	219,409	1,527,828	180	14,201,467	27,214	1,371,741	1,159,805	11,641,483	1,224
Use of Nursing Facilities <sup>c</sup>												
Entire year	4,963	1,108	3,846	8	1	0	51,688	11,052	40,576	56	4	0
Part year	4,187	529	3,601	47	8	2	40,113	4,880	34,809	347	60	17
None	3,243,988	4,460	309,822	464,177	2,464,986	543	23,747,664	41,553	3,094,314	2,365,725	18,242,356	3,716
Maintenance Assistance Statu	ıs											
Cash	562,480	3,915	310,159	77,138	171,268	0	4,902,500	38,407	3,103,636	380,542	1,379,915	0
Medically needy	82,563	0	0	82,037	526	0	538,540	0	0	536,634	1,906	0
Poverty-related	2,207,857	25	31	240,066	1,967,190	545	15,651,377	239	276	1,079,171	14,567,958	3,733
Other/unknown	400,238	2,157	7,079	64,991	326,011	0	2,747,048	18,839	65,787	369,781	2,292,641	0
Managed Care (MC) Status												
Fee-for-service (FFS) all year	2,067,771	5,334	260,522	315,991	1,485,387	537	17,566,129	50,426	2,662,103	1,858,790	12,991,114	3,696
FFS part year, with Rx claims	532,640	189	18,114	87,010	427,321	6	1,545,023	617	80,315	211,014	1,253,046	31
FFS part year, no Rx claims	239,823	30	3,025	20,224	216,542	2	675,401	128	12,287	44,219	618,761	6

a. Table ND.2 includes the beneficiaries represented by Cell K of Table 1. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services. The total includes some beneficiaries with unknown basis of eligibility and some whose age categories are not consistent with basis of eligibility.

c. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; FFS = fee-for-service pharmacy benefit; MAX = Medicaid Analytic Extract; Rx = pharmacy benefit.

TABLE ND.3 ANNUAL MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFICIARY, BY BENEFICIARY CHARACTERISTIC<sup>a, b</sup> NONDUAL BENEFICIARIES, TEXAS, 2005

Beneficiary Characteristics	Percentage with at Least One Rx	Mean Number of Rx	Mean Rx \$	\$ per Rx	Mean \$, All Medicaid FFS \$c	Rx \$ as a Percentage of All Medicaid FFS \$ <sup>d</sup>	Number of Beneficiaries
All	73.2	6.7	\$424	\$ per KX	\$2,496	17.0	3,253,138
Age	70.2	0.7	Ψ+2-+	ΨΟΟ	Ψ2,430	17.0	0,200,100
5 and younger	77.3	6.1	213	35	1,979	10.7	1,208,235
6-14	69.1	5.3	337	64	1,432	23.5	1,016,455
15-20	68.0	5.2	374	71	2,222	16.8	424,543
21-44	75.0	7.6	640	84	4,104	15.6	445,003
45-64	78.5	22.1	2,112	96	9,383	22.5	152,412
65-74	77.6	22.5	1,840	82	9,884	18.6	2,921
75-84	78.1	28.4	2,059	73	11,026	18.7	2,105
85 and older	79.1	34.5	2,238	65	14,865	15.1	1,462
Unknown	0.0	0.0	0	0	277	0.0	2
Basis of Eligibilitye							
Aged	78.2	28.0	2,049	73	11,508	17.8	6,097
Disabled	79.5	19.3	2,100	109	11,182	18.8	317,269
Adults	75.1	5.4	277	52	2,385	11.6	464,232
Children	72.1	5.3	231	44	1,377	16.8	2,464,995
Unknown	28.1	1.9	139	73	2,328	6.0	545
Gender							
Female	74.6	6.9	412	60	2,464	16.7	1,799,707
Male	71.6	6.6	438	67	2,536	17.3	1,453,371
Unknown	23.3	8.1	503	62	4,112	12.2	60
Race							
White	73.8	8.0	626	78	3,303	18.9	745,226
African American	64.1	5.8	393	68	2,255	17.4	622,725
Other/unknown	76.0	6.6	354	54	2,257	15.7	1,885,187
Use of Nursing Facili	ities <sup>f</sup>						
Entire year	96.8	85.4	6,247	73	41,940	14.9	4,963
Part year	95.2	56.8	4,306	76	41,821	10.3	4,187
None	73.2	6.5	410	63	2,385	17.2	3,243,988
Maintenance Assista	nce Status						
Cash	76.8	13.4	1,287	96	6,715	19.2	562,480
Medically needy	71.4	6.6	450	68	2,927	15.4	82,563
Poverty related	73.1	5.2	215	42	1,302	16.5	2,207,857
Other/unknown	69.4	6.1	357	59	3,065	11.6	400,238

a. Table ND.3 includes beneficiaries represented by Cell K of Table 1.

b. The Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. In eight states (DE, IA, IL, NE, NY, TX, UT, and WV) the expenditures in this column include only Rx drug expenditures for those enrolled in capitated managed care plans, and not expenditures for other services covered by the plans or long-term-care services not covered by the plans. As a result, the amounts shown in this column for all Medicaid fee-for-service expenditures are lower than they would otherwise be.

d. In eight states (DE, IA, IL, NE, NY, TX, UT, and WV) the Rx share of expenditures for all Medicaid services shown in this column is higher than it would be if all expenditures for these other services, including services provided in capitated managed care plans and long-term-care services, were included.

e. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability

or blindness. The children's group includes children receiving fost care and adoptive services. f. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.

Bene(s) = beneficiary (or beneficiaries); CMS = Centers for Medicare & Medicaid Services; FFS = fee-for-service; MAX = Medicaid Analytic Extract; OTC = over-the-counter; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.4

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC<sup>A, b</sup>

NONDUAL BENEFICIARIES, TEXAS, 2005

			_		Num	ber of Rx, Po	ercentage w	ith:		_	Numb	er
Beneficiary Characteristics	Mean Number of Rx	Mean Rx \$	Rx \$ as a Percentage of All Medicaid FFS \$ <sup>c</sup>	None		More than 1, but 2 or Less	More than 2, but 5 or Less	More than 5, but 10 or Less	More than 10	Mean \$, All Medicaid FFS \$ <sup>d</sup>	Beneficiaries	Benefit Months
All	0.9	\$58	17.0	26.8	52.1	10.0	7.5	2.4	1.3	\$341	3,253,138	23,839,465
Age												
5 and younger	0.8	29	10.7	22.7	57.1	10.1	6.7	2.1	1.2	269	1,208,235	8,896,395
6-14	0.7	44	23.5	30.9	53.5	7.6	5.6	1.6	0.8	186	1,016,455	7,847,523
15-20	0.7	53	16.8	32.0	50.6	7.9	6.4	2.1	0.9	315	424,543	2,990,832
21-44	1.3	106	15.6	25.0	46.0	13.7	10.0	3.4	1.8	679	445,003	2,687,799
45-64	2.5	237	22.5	21.5	26.6	20.6	21.4	6.3	3.7	1,054	152,412	1,357,366
65-74	2.6	209	18.6	22.4	25.1	20.1	20.1	8.7	3.7	1,122	2,921	25,741
75-84	3.0	215	18.7	21.9	21.9	18.5	19.7	13.8	4.2	1,149	2,105	20,202
85 and older	3.7	241	15.1	20.9	15.2	14.1	25.0	19.8	5.0	1,598	1,462	13,604
Unknown	0.0	0	0.0	100.0	0.0	0.0	0.0	0.0	0.0	184	2	3
Basis of Eligibility	<sub>r</sub> e											
Aged	3.0	217	17.8	21.8	21.9	18.1	20.7	13.3	4.2	1,221	6,097	57,485
Disabled	1.9	210	18.8	20.5	36.5	17.3	17.9	5.2	2.7	1,119	317,269	3,169,699
Adults	1.1	54	11.6	24.9	48.1	13.1	9.0	3.2	1.7	468	464,232	2,366,128
Children	0.7	31	16.8	27.9	54.9	8.5	5.8	1.8	1.0	186	2,464,995	18,242,420
Unknown	0.3	20	6.0	71.9	24.8	2.8	0.4	0.0	0.2	340	545	3,733
Gender												
Female	1.0	58	16.7	25.4	52.3	10.5	7.8	2.6	1.4	347	1,799,707	12,788,819
Male	0.9	58	17.3	28.4	51.8	9.5	7.0	2.1	1.1	334	1,453,371	11,050,314
Unknown	1.5	91	12.2	76.7	13.3	1.7	0.0	8.3	0.0	743	60	332
Race												
White	1.1	86	18.9	26.2	49.9	10.9	8.8	2.7	1.6	453	745,226	5,432,441
African American	0.9	58	17.4	35.9	45.0	8.2	7.0	2.6	1.4	334	622,725	4,205,557
Other/unknown	0.9	47	15.7	24.0	55.3	10.3	7.1	2.2	1.1	300	1,885,187	14,201,467
Use of Nursing Fa	cilitiesf											
Entire year	8.2	600	14.9	3.2	2.5	3.8	21.4	43.7	25.4	4,027	4,963	51,688
Part year	5.9	450	10.3	4.8	7.8	8.6	34.7	29.9	14.3	4,365	4,187	40,113
None	0.9	56	17.2	26.8	52.2	10.1	7.4	2.3	1.2	326	3,243,988	23,747,664
Maintenance Assi	stance Status	;										
Cash	1.5	148	19.2	23.2	42.8	14.5	13.4	3.8	2.2	770	562,480	4,902,500
Medically needy	1.0	69	15.4	28.6	46.0	16.9	7.8	0.4	0.2	449	82,563	538,540
Poverty related	0.7	30	16.5	26.9	54.5	9.0	6.3	2.2	1.2	184	2,207,857	15,651,377
Other/unknown	0.9	52	11.6	30.6	53.1	8.4	5.6	1.6	0.8	447	400,238	2,747,048

a. Table ND.4 includes the beneficiaries represented by Cell K of Table 1. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. The Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. In eight states (DE, IA, IL, NE, NY, TX, UT, and WV) the expenditures in this column include only Rx drug expenditures for those enrolled in capitated managed care plans, and not expenditures for other services covered by the plans or long-term-care services not covered by the plans. As a result, the amounts shown in this column for all Medicaid fee-for-service expenditures are lower than they would otherwise be.

d. In eight states (DE, IA, IL, NE, NY, TX, UT, and WV) the Rx share of expenditures for all Medicaid services shown in this column is higher than it would be if all expenditures for these other services, including services provided in capitated managed care plans and long-term-care services, were included.

e. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability

or blindness. The children's group includes children receiving foster care and adoptive services.

f. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; FFS = fee-for-service; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.5

AVERAGE MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BRAND STATUS AND BENEFICIARY CHARACTERISTIC<sup>A, b, c</sup>

NONDUAL BENEFICIARIES, TEXAS, 2005

		All Rx		Patented	ม Brand Drugs	d-Name	Off-Pater	nt Bran Drugs	id-Name	Gen	eric Dı	ruas
Beneficiary	Number	7 1		Number	2.490		Number	z.ugo		Number	00 2.	ugo
Characteristics	of Rx	Rx\$	\$ per Rx	of Rx	Rx\$	\$ per Rx	of Rx	Rx\$	\$ per Rx	of Rx	Rx\$	\$ per Rx
All	0.9	\$58	\$63	0.3	\$43	\$133	0.1	\$4	\$56	0.5	\$10	\$20
Age												
5 and younger	0.8	29	35	0.2	17	77	0.1	3	35	0.5	8	16
6-14	0.7	44	64	0.3	33	120	0.1	4	56	0.3	7	20
15-20	0.7	53	71	0.3	42	145	0.1	4	66	0.4	7	19
21-44	1.3	106	84	0.4	83	186	0.1	7	90	0.7	16	22
45-64	2.5	237	96	1.0	186	184	0.1	12	133	1.4	39	28
65-74	2.6	209	82	1.1	167	147	0.1	7	83	1.3	35	26
75-84	3.0	215	73	1.3	171	128	0.1	7	70	1.5	37	24
85 and older	3.7	241	65	1.6	190	118	0.1	8	59	2.0	43	22
Unknown	0.0	0	0	0.0	0	0	0.0	0	0	0.0	0	(
Basis of Eligibility	rd											
Aged	3.0	217	73	1.3	173	131	0.1	7	68	1.5	38	24
Disabled	1.9	210	109	0.8	171	206	0.1	11	122	1.0	28	27
Adults	1.1	54	52	0.3	38	116	0.1	4	60	0.7	12	18
Children	0.7	31	44	0.2	21	91	0.1	3	42	0.4	7	17
Unknown	0.3	20	73	0.1	16	167	0.0	1	70	0.2	3	21
Gender												
Female	1.0	58	60	0.3	42	128	0.1	5	57	0.6	11	20
Male	0.9	58	67	0.3	44	139	0.1	4	55	0.5	9	20
Unknown	1.5	91	62	0.6	75	128	0.1	2	25	0.8	14	17
Race												
White	1.1	86	78	0.4	67	153	0.1	6	77	0.6	14	23
African American	0.9	58	68	0.3	45	144	0.1	4	69	0.5	9	19
Other/unknown	0.9	47	54	0.3	34	118	0.1	4	48	0.5	9	19
Use of Nursing Fa	cilitiese											
Entire year	8.2	600	73	3.3	465	140	0.2	22	94	4.6	113	24
Part year	5.9	450	76	2.2	337	153	0.2	23	118	3.5	90	25
None	0.9	56	63	0.3	42	133	0.1	4	56	0.5	10	20
Maintenance Assi	stance Sta	tus										
Cash	1.5	148	96	0.6	118	190	0.1	9	97	0.8	21	25
Medically needy	1.0	69	68	0.3	52	152	0.0	4	84	0.6	13	21
Poverty related	0.7	30	42	0.2	20	88	0.1	3	41	0.4	7	17
Other/unknown	0.9	52	59	0.3	40	120	0.1	4	57	0.5	9	18

a. Table ND.5 includes the beneficiaries represented by Cell K of Table 1. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. The Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. Brand-name drugs, sometimes called "innovator single-source drugs," are drugs whose patents have not yet expired. Off-patent brand-name drugs, sometimes called "innovator multiple-source drugs," are brand-name drugs whose patents have expired. Generic drugs, sometimes called "non-innovator multiple-source drugs," are off-patent drugs manufactured and sold by companies other than the original patent holder. In Texas, 0.7 percent of drug claims have missing values for brand status. Thus, the sum of the three groups in this table may be smaller than all prescriptions combined. For information about this classification method, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

d. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability

or blindness. The children's group includes children receiving foster care and adoptive services.

e. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.

CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.6

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY BRAND STATUS AND THERAPEUTIC CATEGORY<sup>a, b, c, d</sup>
NONDUAL BENEFICIARIES, TEXAS, 2005

		nber of R Month Am			\$ pe	r Benefit I Us	Month Am ers	nong		\$ per	Rx					Userse	
Therapeutic Category	F Total	Patented Brand- Name	Brand-	Generic		Patented Brand- Name	Brand-	Seneric	F Total	Patented Brand- Name	Brand-	Generic	Total Number of Rx	Total Rx \$	Number of Users	As a Percentage of All Benes	Number of Benefit Months
Anti-infective Agents	0.3	0.1	0.0	0.2	\$14	\$9	\$2	\$4	\$50	\$96	\$67	\$22	4,170,981	\$207,870,693	1,672,485	51.4	14,356,433
Biologicals	0.3	0.2	0.0	0.0	697	544	123	30	2418	2,349	3,486	1,404	1,657	4,006,718	757	0.0	5,748
Antineoplastic Agents	0.4	0.1	0.0	0.3	128	105	3	21	315	895	191	75	31,588	9,960,463	7,905	0.2	77,794
Endocrine/Metabolic Drugs	0.3	0.1	0.0	0.2	23	15	3	5	77	174	84	26	1,190,282	91,726,552	461,544	14.2	4,035,769
Cardiovascular Agents	0.7	0.3	0.0	0.4	46	38	0	8	65	125	61	20	1,144,659	74,192,894	167,616	5.2	1,614,488
Respiratory Agents	0.4	0.1	0.1	0.2	18	13	2	3	43	89	29	15	5,643,236	240,092,433	1,525,079	46.9	13,240,624
Gastrointestinal Agents	0.3	0.2	0.0	0.1	26	24	1	2	86	142	55	16	797,347	68,262,722	284,596	8.7	2,603,036
Genitourinary Agents	0.3	0.1	0.0	0.1	14	8	2	3	55	86	60	28	234,859	12,828,726	125,802	3.9	934,775
CNS Drugs	0.6	0.3	0.0	0.3	84	76	1	7	132	223	151	24	1,814,753	239,427,646	304,631	9.4	2,846,869
Stimulants/Anti-obesity/Anorexia	0.6	0.5	0.0	0.1	65	61	1	3	110	120	106	39	602,091	66,500,403	107,258	3.3	1,028,689
Miscellaneous Psychological/ Neurological Agents Analgesics and Anesthetics	0.4	0.4	0.0	0.1 0.3	143 10	138 5		5 4	339 33	388 214	145 234	77 15	25,620 2,434,695	8,687,502 81,081,175	,	0.2 30.1	60,683 8,527,321
Neuromuscular Agents	0.5	0.2	0.0	0.3	61	45		11	112	206	151	38	, - ,	98,217,401	164,136	5.0	1,601,311
Nutritional Products	0.2	0.1	0.0	0.2	6	3		2	23	41	35	13	,	11,095,271	254,576	7.8	1,918,419
Hematological Agents	0.3	0.2	0.0	0.1	100	96		3	311	596	58	21	178,061	55,313,635	,	2.1	552,800
Topical Products	0.2	0.1	0.0	0.1	11	8	0	3	44	80	49	20	•	98,488,786	,	31.6	9,106,839
Miscellaneous Products	0.4	0.1	0.0	0.1	159	121	22	16	377	677	448	82		9,183,658	, ,	0.2	57,871
Unknown Therapeutic Category	0.4	0.2	0.0	0.0	3	0	0	0	24	0//	0	02	,	686,394	21,811	0.2	201,935
TOTAL NO. OF RX AND RX \$	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	21,898,972	1,377,623,072	n.a.	n.a.	n.a.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; CNS = Central Nervous System; MAX = Medicaid Analytic Extract; n.a. = not applicable; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

a. Table ND.6 includes the beneficiaries represented by Cell K of Table 1. A beneficiary who used drugs from two or more categories was counted as a user for each category. Therefore, the sum

of users across categories may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. For information about these therapeutic categories, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

d. Brand-name drugs, sometimes called "innovator single-source drugs," are drugs whose patents have not yet expired. Off-patent brand-name drugs, sometimes called "innovator multiple-source drugs," are brand-name drugs whose patents have expired. Generic drugs, sometimes called "non-innovator multiple-source drugs," are off-patent drugs manufactured and sold by companies other than the original patent holder. In Texas, 0.7 percent of drug claims have missing values for brand status. Thus, the sum of the three groups in this table may be smaller than all prescriptions combined. For information about this classification method, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

e. A user is a beneficiary who had at least one prescription filled in a given therapeutic category during 2005.

### TABLE ND.7 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY TOP 10 DRUG GROUP<sup>a, b, c</sup> NONDUAL BENEFICIARIES, TEXAS, 2005

			Users		An	nong Usei	S
Top 10 Drug Groups	Total Medicaid Rx	Number of Users	As a Percentage of All Beneficiaries	Number of Benefit Months		\$ per Rx	Rx \$ per Benefit Month
ANTIPSYCHOTICS	\$159,260,426	109,467	3.4	1,132,863	0.5	\$295	\$141
ANTIASTHMATIC	117,590,071	774,295	23.8	7,198,151	0.2	70	16
ANTICONVULSANT	87,227,751	104,324	3.2	1,079,073	0.5	152	81
STIMULANTS/ANTI-OBESITY/ANOREXIANTS	64,299,930	122,433	3.8	1,198,824	0.5	111	54
DERMATOLOGICAL	63,825,164	1,048,168	32.2	9,804,410	0.2	43	7
COUGH/COLD/ALLERGY	60,806,626	1,695,436	52.1	15,734,810	0.2	22	4
ANTIDEPRESSANTS	54,423,336	185,262	5.7	1,780,451	0.4	82	31
CEPHALOSPORINS	53,033,161	655,452	20.1	6,187,412	0.1	61	9
ULCER DRUGS	47,236,266	205,307	6.3	1,930,425	0.3	94	24
ANTIVIRAL	41,185,041	81,842	2.5	793,652	0.2	300	52
Total	748,887,772	4,981,986		46,840,071	n.a.	n.a.	n.a.

Source: Data for this table are from the MAX 2005 file for Texas, released by CMS in 10/2008. This table was produced on 04/23/2009.
a. Table ND.7 includes the beneficiaries represented by Cell K of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2005. A beneficiary who used drugs from two or more groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2005. For information about these drug groups, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$

<sup>=</sup> Medicaid reimbursement.

# TABLE ND.7A MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR TOP 10 DRUG GROUPS COMBINED AND FIRST AND SECOND GROUPS SEPARATELY, BY SEX, BASIS OF ELIGIBILITY, AND AGE<sup>a, b, c</sup> NONDUAL BENEFICIARIES, TEXAS, 2005

	All Top 1	10 Drug Groups		ANT	IPSYCHOTI	CS			AN	FIASTHMAT	IC	
Beneficiary Characteristics	Number of Rx	Rx \$	Number of Users	Users as % of All Benes	Number of Benefit Months Among Users	Mean Number of Rx per Benefit Month		Number of Users	Users as % of All Benes	Number of Benefit Months Among Users	Mean Number of Rx per Benefit Month	
All	9,820,611		109,467	3.4	1,132,863	0.5		774,295	23.8	7,198,151	0.2	
Female	-,-	, ,,,,,			, - ,		,	,		,, -		•
All Females	4,999,094	375,084,878	52,944	2.9	538,399	0.5	134	369,282	20.5	3,418,117	0.2	16
Female, Disabled												
All Ages	1,282,271	177,315,350	33,450	21.2	363,663	0.5	151	51,206	32.5	563,307	0.3	26
5 and younger	58,019	4,140,734	200	2.4	2,239	0.4	79	5,186	62.0	56,600	0.3	27
6-14	150,429	16,540,218	2,803	16.0	31,048	0.5	117	7,194	41.2	82,046	0.3	24
15-20	100,591	13,477,076	2,813	21.6	30,953	0.5	134	3,572	27.5	40,588	0.3	22
45-64	359,486	60,010,433	13,249	28.8	142,016	0.4	155	10,493	22.8	113,737	0.3	22
45-64	612,950	83,078,834	14,363	19.8	157,265	0.5	159	24,715	34.1	270,059	0.3	29
65-74	680	55,543	16	9.4	107	0.5	111	37	21.6	217	0.3	25
75-84	56	8,455	3	10.7	17	1.1	168	7	25.0	48	0.3	77
85 and older	60	4,057	3	23.1	18	0.4	37	2	15.4	12	0.3	70
Female, Other Eligibles												
All Ages	3,716,823	197,769,528	19,494	1.2	174,736	0.4	98	318,076	19.4	2,854,810	0.2	14
5 and younger	1,762,320	62,660,667	571	0.1	5,778	0.4	76	153,842	26.5	1,427,167	0.2	12
6-14	1,105,157	68,392,979	6,225	1.3	63,367	0.5	109	105,488	22.0	969,867	0.2	16
15-20	387,252	27,277,223	5,058	2.2	47,093	0.5	99	29,079	12.6	248,936	0.2	15
21-44	384,654	31,652,790	6,287	1.9	45,943	0.3	81	26,050	8.0	177,390	0.3	15
45-64	46,879	4,915,560	664	3.2	5,348	0.3	78	2,626	12.8	21,093	0.3	23
65-74	11,111	1,189,600	230	14.2	2,445	0.7	180	382	23.6	4,088	0.3	24
75-84	9,969	874,529	225	18.3	2,371	0.6	106	301	24.4	3,147	0.3	20
85 and older	9,481	806,180	234	23.0	2,391	0.6	101	308	30.3	3,122	0.3	20
Male												
All Males	4,821,380	373,788,009	56,517	3.9	594,403	0.5	147	405,010	27.9	3,780,014	0.2	17
Male, Disabled												
All Ages	1,156,813	173,631,870	36,728	23.0	401,037	0.5	163	44,000	27.5	485,024	0.3	26
5 and younger	89,947	6,794,903	639	5.4	6,882	0.4	83	8,239	69.8	90,486	0.3	27
6-14	337,479	39,375,834	8,881	25.1	98,418	0.5	125	15,019	42.4	169,349	0.3	24
15-20	154,260	22,529,000	5,326	25.7	58,728	0.5	152	5,179	25.0	58,823	0.3	23
21-44	280,650	58,526,427	13,162	31.5	143,676	0.5	191	4,817	11.5	52,711	0.3	23
45-64	293,933	46,359,324	8,707	17.5	93,254	0.5	172	10,696	21.5	113,377	0.3	30
65-74	523	45,603	13	9.5	79	0.5	107	47	34.3	260	0.5	32
75-84	2	40	0	0.0	0	0.0	0	0	0.0	0	0.0	0
85 and older	19	739	0	0.0	0	0.0	0	3	100.0	18	0.2	2

# TABLE ND.7A MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR TOP 10 DRUG GROUPS COMBINED AND FIRST AND SECOND GROUPS SEPARATELY, BY SEX, BASIS OF ELIGIBILITY, AND AGE<sup>a, b, c</sup> NONDUAL BENEFICIARIES, TEXAS, 2005

	All Top 1	Drug Groups		ANTI	PSYCHOTIC	S			AN	TIASTHMATI	С	
				Users	Number of Benefit N	Mean lumber of	Mean		Users	Number of Benefit N	Mean Number of	Mean
Beneficiary Characteristics	Number of Rx	Rx \$	Number of Users	as % of All Benes	Months Among Users	Rx per I Benefit Month	Rx \$ per Benefit Month	Number of Users	as % of All Benes	Months Among Users	Rx per l Benefit Month	Rx \$ per Benefit Month
Male, Other Eligibles												
All Ages	3,664,567	200,156,139	19,789	1.5	193,366	0.5	113	361,010	27.9	3,294,990	0.2	15
5 and younger	1,993,852	75,237,141	1,348	0.2	13,549	0.4	72	202,215	33.3	1,859,038	0.2	14
6-14	1,300,079	92,400,799	12,039	2.5	120,201	0.5	115	132,206	27.3	1,201,471	0.3	18
15-20	308,703	25,575,531	5,117	3.2	49,077	0.5	121	23,596	14.8	210,928	0.2	17
21-44	33,397	3,750,105	718	2.3	5,238	0.3	102	1,750	5.7	12,531	0.3	19
45-64	13,844	1,796,442	199	2.1	1,544	0.3	90	705	7.3	5,385	0.3	26
65-74	5,867	622,619	157	15.8	1,583	0.7	152	181	18.2	1,913	0.3	21
75-84	5,351	502,606	131	15.7	1,372	0.6	112	205	24.6	2,215	0.3	22
85 and older	3,474	270,896	80	18.8	802	0.7	91	152	35.7	1,509	0.2	16
Unknown	137	14,885	6	9.7	61	0.4	72	3	4.8	20	0.2	21

Source: Data for this table are from the MAX 2005 file for Texas, released by CMS in 10/2008. This table was produced on 04/23/2009.

a. Table ND.7A includes the beneficiaries represented by Cell K of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2005. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2005. For information about these drug groups, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription (s) or pharmacy benefit; \$ = Medicaid reimbursement.

### TABLE ND.7B MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR THIRD TO FIFTH TOP DRUG GROUPS SEPARATELY,

### BY SEX, BASIS OF ELIGIBILITY, AND AGE<sup>a, b, c</sup> NONDUAL BENEFICIARIES, TEXAS, 2005

ANTICONVULSANT STIMULANTS/ANTI-OBESITY/ANOREXIANTS DERMATOLOGICAL Mean Mean Mean Number of Number Number of Number Number of Number Users Mean Benefit Mean Mean Benefit of Rx Users of Rx Users Benefit of Rx as % per Rx \$ per as % Months per Rx \$ per per Rx \$ per Months as % Months Among Benefit Benefit Among Benefit Number of of All Benefit Number of of All Number of of All Benefit Among Benefit **Beneficiary Characteristics** Month Users Benes Users Month Month Users Benes Users Month Month Users Benes Users Month ΑII 104.324 3.2 1,079,073 0.5 \$81 122,433 3.8 1.198.824 0.5 \$54 1.048.168 32.2 9,804,410 0.2 \$7 Female All Females 60,486 3.4 615,497 0.5 77 35.349 2.0 347,464 0.5 52 563,829 31.3 5,232,155 0.2 7 Female, Disabled All Ages 39.454 25.1 435.146 0.5 86 8.170 5.2 90.716 0.5 57 50.155 31.8 563.584 0.2 9 93 35 958 11.4 10,520 0.6 372 4.4 4,140 0.3 4,753 56.8 52,478 0.2 5 5 and younger 7 6-14 3,481 19.9 39,265 0.7 114 4,735 27.1 52,852 0.5 54 8,058 46.1 92,282 0.1 23.4 15-20 3,041 34,204 0.7 131 1,411 10.8 15,801 0.4 53 4,939 38.0 56,646 0.1 9 97 9 21-44 14,244 31.0 156,179 0.5 948 2.1 10,237 68 12,090 26.3 135,397 0.2 0.4 83 45-64 17,698 24.4 194,792 0.5 64 704 1.0 7,686 0.4 20,276 28.0 226,483 0.2 11 65-74 29 17.0 0.7 47 0 0.0 0 32 18.7 165 0 0.0 224 0.2 11 75-84 2 7.1 9 0.7 122 0 0.0 0 0.0 0 0 0.0 0 0.0 0 85 and older 1 7.7 12 0.3 4 0 0.0 0 0.0 0 53.8 74 0.4 10 Female, Other Eligibles All Ages 21,032 1.3 180,351 0.4 56 27,179 1.7 256,748 0.5 51 513,674 31.3 4,668,571 0.2 7 5 and younger 1,353 0.2 12,634 0.5 58 1,716 0.3 17,287 0.3 37 274,496 47.2 2,510,474 0.2 5 6-14 4,088 0.9 39,870 0.5 67 19,689 4.1 187,880 0.5 51 145,624 30.4 1,390,618 0.1 8 4,211 1.8 38.450 0.5 66 4.224 1.8 39.833 0.4 52 52.977 22.9 473.828 0.2 10 15-20 21-44 9,243 2.8 70,437 47 1,405 53 36,186 252,942 9 0.4 0.4 10,541 0.4 11.1 0.2 45-64 1,570 7.6 12.853 0.3 41 123 0.6 975 0.5 67 2.912 14.2 24,618 10 0.2 5,106 65-74 264 16.3 2,900 0.6 43 4 0.2 36 1.1 333 471 29.1 0.2 9 0.6 75-84 180 1,974 40 9 0.7 93 0.3 28 539 43.8 5,926 12 14.6 0.2 9 85 and older 123 12.1 1,233 0.6 36 0.9 103 0.5 86 469 46.1 5,059 0.2 10 Male All Males 43,835 3.0 463,540 0.6 86 87,082 6.0 851,346 0.5 54 484,332 33.3 4,572,178 0.2 6 Male, Disabled All Ages 31,398 19.7 347,579 0.6 95 23,494 14.7 259,621 0.5 57 44,732 28.0 502,279 0.2 9 1,353 11.5 14,987 92 1,240 10.5 13.587 38 6.525 55.3 72.529 5 5 and younger 0.6 0.4 0.1 6-14 6,170 17.4 69,420 0.6 97 16,900 47.7 186,601 0.5 58 12,834 36.2 146,669 0.1 7 15-20 4,102 19.8 46,218 0.7 125 4,189 20.2 46,475 0.5 59 6,831 32.9 78,211 0.2 9 21-44 10,953 26.2 121.502 0.6 109 895 2.1 10,062 0.4 69 8.603 20.6 96.669 0.2 11 74 19.9 107,921 11 45-64 8,804 17.7 95,359 0.5 61 269 0.5 2,888 0.4 9,904 0.2 65-74 15 10.9 81 0.6 65 1 0.7 8 0.1 23 33 24.1 265 0.3 14 75-84 1 10.0 12 0.1 3 0 0.0 0 0.0 0 0 0.0 0 0.0 0 0.0 0 0 0 0.0 0 0.0 0 2 66.7 15 0.3 11 85 and older 0.0 0

### TABLE ND.7B MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR THIRD TO FIFTH TOP DRUG GROUPS SEPARATELY,

BY SEX, BASIS OF ELIGIBILITY, AND AGE<sup>a, b, c</sup> NONDUAL BENEFICIARIES, TEXAS, 2005

		ANTIC	ONVULSAN	NT		STIMULAN	ITS/ANTI	-OBESITY/	ANOREX	IANTS	<u> </u>	DERM	ATOLOGIC	AL	
				Mean					Mean					Mean	
		Users	Number of Benefit	Number of Rx	Mean		Users	Number of Benefit	Number of Rx	Mean		Users	Number of Benefit	Number of Rx	Mean
		as %	Months		Rx \$ per		as %	Months		Rx \$ per		as %	Months		Rx \$ per
	Number of	of All	Among	Benefit		Number of	of All	Among	Benefit		Number of	of All	Among		Benefit
Beneficiary Characteristics	Users		Users		Month		Benes	Users					Users		Month
Male, Other Eligibles															
All Ages	12,437	1.0	115,961	0.5	60	63,588	4.9	591,725	0.5	53	439,600	34.0	4,069,899	0.1	6
5 and younger	1,834	0.3	17,490	0.4	47	4,705	0.8	46,463	0.3	34	275,545	45.4	2,513,208	0.2	5
6-14	5,510	1.1	54,256	0.5	63	50,587	10.4	468,633	0.5	54	119,175	24.6	1,141,413	0.1	6
15-20	2,845	1.8	26,332	0.5	71	8,043	5.0	74,722	0.5	58	40,389	25.3	378,038	0.2	11
21-44	1,384	4.5	10,538	0.4	43	216	0.7	1,614	0.4	58	2,673	8.7	20,637	0.2	9
45-64	607	6.3	4,615	0.3	42	33	0.3	260	0.4	51	999	10.4	7,869	0.2	10
65-74	113	11.4	1,219	0.6	53	3	0.3	31	0.3	36	299	30.1	3,186	0.2	13
75-84	95	11.4	1,001	0.5	44	1	0.1	2	1.5	136	315	37.9	3,365	0.2	10
85 and older	49	11.5	510	0.6	37	0	0.0	0	0.0	0	205	48.1	2,183	0.2	11
Unknown	3	4.8	36	0.5	60	2	3.2	14	0.4	36	7	11.3	77	0.3	41

Source: Data for this table are from the MAX 2005 file for Texas, released by CMS in 10/2008. This table was produced on 04/23/2009.

a. Table ND.7B includes the beneficiaries represented by Cell K of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2005. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2005. For information about these drug groups, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription (s) or pharmacy benefit; \$ = Medicaid reimbursement.

## ${\it TABLE~ND.7C}\\ {\it MEDICAID~PHARMACY~BENEFIT~USE~AND~REIMBURSEMENT~FOR~SIXTH~TO~EIGHTH~TOP~DRUG~GROUPS~SEPARATELY,}$

### BY SEX, BASIS OF ELIGIBILITY, AND AGE<sup>a, b, c</sup> NONDUAL BENEFICIARIES, TEXAS, 2005

				RGY			, v . IL	DEPRESSAN				JL: 1	HALOSPORI		
Beneficiary Characteristics	Number of Users	Users as % of All Benes	Number of Benefit N Months Among Users	Mean lumber of Rx per F Benefit Month		Number of Users	Users as % of All Benes	Number of Benefit I Months Among Users	Mean Number of Rx per Benefit Month		Number of Users	Users as % of All Benes	Number of Benefit N Months Among Users	Mean Number of Rx per l Benefit Month	
All	1,695,436	52.1	15,734,810	0.2	\$4	185,262	5.7	1,780,451	0.4	\$31	655,452	20.1	6,187,412	0.1	\$9
Female															
All Females	876,483	48.7	8,092,724	0.2	4	127,468	7.1	1,192,320	0.4	32	350,313	19.5	3,254,324	0.1	8
Female, Disabled															
All Ages	62,994	40.0	709,129	0.2	4	59,263	37.6	646,708	0.4	36	28,453	18.1	321,262	0.1	7
5 and younger	6,950	83.1	76,821	0.2	4	91	1.1	1,027	0.3	11	3,627	43.3	40,209	0.1	9
6-14	10,627	60.8	121,784	0.1	4	2,404	13.8	26,905	0.4	25	5,207	29.8	60,104	0.1	10
15-20	5,815	44.7	67,144	0.1	3	3,447	26.5	38,409	0.4	29	2,800	21.5	32,139	0.1	8
21-44	15,889	34.5	177,222	0.1	4	19,748	42.9	213,087	0.4	36	6,906	15.0	77,369	0.1	6
45-64	23,681	32.7	265,882	0.2	4	33,514	46.3	366,901	0.4	37	9,899	13.7	111,327	0.1	5
65-74	29	17.0	240	0.2	7	53	31.0	342	0.5	35	12	7.0	92	0.2	8
75-84	2	7.1	24	0.1	3	3	10.7	12	0.5	31	0	0.0	0	0.0	0
85 and older	1	7.7	12	0.1	4	3	23.1	25	0.5	50	2	15.4	22	0.1	5
Female, Other Eli	gibles														
All Ages	813,489	49.5	7,383,595	0.2	4	68,205	4.2	545,612	0.3	27	321,860	19.6	2,933,062	0.1	9
5 and younger	448,781	77.2	4,079,523	0.2	4	449	0.1	4,720	0.3	9	161,591	27.8	1,526,505	0.1	8
6-14	240,099	50.2	2,272,939	0.2	4	9,942	2.1	98,640	0.4	21	90,445	18.9	867,036	0.1	10
15-20	65,019	28.1	590,582	0.1	4	15,198	6.6	132,792	0.4	24	31,975	13.8	274,094	0.1	7
21-44	54,205	16.6	393,107	0.2	4	36,686	11.2	259,118	0.3	29	35,445	10.9	243,446	0.2	6
45-64	4,532	22.1	37,875	0.2	4	4,786	23.3	38,082	0.3	33	1,858	9.0	15,974	0.1	6
65-74	442	27.3	4,897	0.2	5	384	23.7	4,227	0.5	35	188	11.6	2,048	0.1	6
75-84	260	21.1	2,972	0.2	5	389	31.6	4,191	0.5	39	184	14.9	2,018	0.1	7
85 and older	151	14.8	1,700	0.2	4	371	36.5	3,842	0.6	41	174	17.1	1,941	0.1	7
Male															
All Males	818,948	56.3	7,642,047	0.2	4	57,788	4.0	588,063	0.4	29	305,137	21.0	2,933,068	0.1	9
Male, Disabled															
All Ages	53,376	33.4	600,617	0.2	4	32,951	20.6	356,123	0.4	32	26,080	16.3	294,560	0.1	8
5 and younger	10,190	86.3	112,973	0.2	4	234	2.0	2,547	0.3	14	5,177	43.8	57,644	0.1	9
6-14	19,373	54.7	221,004	0.1	4	5,499	15.5	61,374	0.4	23	8,495	24.0	97,338	0.1	10
15-20	7,529	36.3	86,100	0.1	4	4,110	19.8	45,410	0.4	31	3,457	16.7	39,691	0.1	8
21-44	8,021	19.2	89,968	0.1	4	10,474	25.0	112,629	0.4	36	4,300	10.3	48,613	0.1	6
45-64	8,250	16.6	90,485	0.2	4	12,611	25.3	134,015	0.4	34	4,639	9.3	51,187	0.1	5
65-74	13	9.5	87	0.2	4	22	16.1	145	0.6	26	12	8.8	87	0.2	10
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
85 and older	0	0.0	0	0.0	0	1	33.3	3	0.7	49	0	0.0	0	0.0	0

### TABLE ND.7C MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR SIXTH TO EIGHTH TOP DRUG GROUPS SEPARATELY,

### BY SEX, BASIS OF ELIGIBILITY, AND AGE<sup>a, b, c</sup> NONDUAL BENEFICIARIES, TEXAS, 2005

	-	COUG	H/COLD/ALLE	RGY			ANTIC	EPRESSAN	ITS			CEPI	HALOSPORII	1S	
		Llaara	Number of	Mean	Maan			Number of	Mean Jumber of	Maan		Llaava	Number of	Mean Jumber of	Mean
		Users as %	Benefit N Months		Mean Rx \$ per		Users as %	Months		Mean Rx \$ per		Users as %	Months		Rx \$ per
Beneficiary	Number of	of All	Among	Benefit		Number of	of All	Among	Benefit	Benefit	Number of	of All	Among	Benefit	Benefit
Characteristics	Users	Benes	Users	Month	Month	Users	Benes	Users	Month	Month	Users	Benes	Users	Month	Month
Male, Other Elig	ibles														
All Ages	765,572	59.2	7,041,430	0.2	4	24,837	1.9	231,940	0.4	23	279,057	21.6	2,638,508	0.1	9
5 and younger	484,703	79.9	4,392,217	0.2	4	670	0.1	6,948	0.3	9	174,830	28.8	1,648,739	0.1	9
6-14	229,278	47.3	2,172,046	0.1	4	12,133	2.5	119,361	0.4	20	82,948	17.1	795,167	0.1	10
15-20	45,923	28.8	432,676	0.1	4	7,717	4.8	71,506	0.4	25	18,352	11.5	170,970	0.1	7
21-44	4,081	13.3	30,455	0.2	4	2,703	8.8	20,312	0.3	29	2,022	6.6	15,451	0.1	7
45-64	1,153	12.0	9,275	0.2	4	1,103	11.5	8,500	0.3	32	623	6.5	5,126	0.1	8
65-74	216	21.7	2,344	0.1	3	198	19.9	2,073	0.5	33	110	11.1	1,228	0.1	7
75-84	156	18.8	1,738	0.2	5	180	21.6	1,882	0.5	40	110	13.2	1,163	0.1	7
85 and older	62	14.6	679	0.1	3	133	31.2	1,358	0.5	32	62	14.6	664	0.1	8
Unknown	5	8.1	39	0.1	3	6	9.7	68	0.6	33	2	3.2	20	0.1	5

Source: Data for this table are from the MAX 2005 file for Texas, released by CMS in 10/2008. This table was produced on 04/23/2009.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription (s) or pharmacy benefit; \$ = Medicaid reimbursement.

a. Table ND.7C includes the beneficiaries represented by Cell K of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2005. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2005. For information about these drug groups, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

## TABLE ND.7D MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR NINTH AND TENTH TOP DRUG GROUPS

SEPARATELY, BY SEX, BASIS OF ELIGIBILITY, AND AGE<sup>a, b, c</sup> NONDUAL BENEFICIARIES, TEXAS, 2005

		UL	CER DRUGS					ANTIVIRAL				
		Users	Number of Benefit N	Mean	Mean		Users	Number of	Mean Jumber of	Mean		
		as %	Months	Rx per F			as %	Months	Rx per F			
Beneficiary	Number of	of All	Among			Number of	of All	Among	Benefit		Number of	Number of
Characteristics	Users	Benes	Users	Month	Month	Users	Benes	Users	Month	Month	Beneficiaries	Benefit Months
All	205,307	6.3	1,930,425	0.3	\$25	81,842	2.5	793,652	0.2	\$52	3,253,138	23,839,465
Female												
All Females	129,275	7.2	1,201,970	0.3	25	45,559	2.5	429,940	0.2	48	1,799,706	12,788,817
Female, Disable	t											
All Ages	41,008	26.0	451,782	0.4	42	7,616	4.8	82,261	0.3	153	157,484	1,590,305
5 and younger	1,315	15.7	13,668	0.3	26	276	3.3	3,109	0.2	13	8,367	81,257
6-14	1,748	10.0	20,037	0.3	37	670	3.8	7,705	0.2	53	17,471	185,808
15-20	1,920	14.8	21,747	0.3	32	470	3.6	5,331	0.2	69	13,007	136,522
21-44	9,900	21.5	108,667	0.3	37	3,047	6.6	31,789	0.3	179	46,021	464,249
45-64	26,074	36.0	287,332	0.4	46	3,149	4.3	34,294	0.3	177	72,406	721,368
65-74	43	25.1	289	0.5	46	4	2.3	33	0.2	12	171	920
75-84	5	17.9	33	0.2	11	0	0.0	0	0.0	0	28	115
85 and older	3	23.1	9	0.4	43	0	0.0	0	0.0	0	13	66
Female, Other El	igibles											
All Ages	88,267	5.4	750,188	0.2	15	37,943	2.3	347,679	0.1	23	1,642,222	11,198,512
5 and younger	21,835	3.8	189,090	0.2	8	12,554	2.2	126,988	0.1	5	581,440	4,257,383
6-14	20,458	4.3	198,536	0.1	10	12,150	2.5	121,652	0.1	11	478,620	3,622,025
15-20	14,816	6.4	130,100	0.2	14	4,888	2.1	42,904	0.2	22	231,321	1,507,274
21-44	25,834	7.9	185,682	0.3	24	7,862	2.4	51,917	0.3	85	326,441	1,653,005
45-64	3,908	19.0	31,718	0.3	36	414	2.0	3,391	0.3	159	20,534	122,310
65-74	587	36.3	6,307	0.4	42	30	1.9	338	0.2	60	1,617	15,093
75-84	447	36.3	4,813	0.5	44	26	2.1	295	0.1	10	1,232	11,877
85 and older	382	37.6	3,942	0.6	56	19	1.9	194	0.1	9	1,017	9,545
Male												
All Males	76,029	5.2	728,420	0.3	23	36,283	2.5	363,712	0.2	57	1,453,370	11,050,313
Male, Disabled												
All Ages	23,497	14.7	255,113	0.4	42	8,334	5.2	86,047	0.4	203	159,782	1,579,388
5 and younger	1,688	14.3	17,974	0.3	26	462	3.9	5,213	0.1	10	11,809	116,394
6-14	2,576	7.3	29,422	0.3	34	1,145	3.2	13,125	0.2	41	35,417	372,773
15-20	2,000	9.6	22,578	0.3	35	497	2.4	5,641	0.2	49	20,736	214,491
21-44	5,586	13.4	61,195	0.4	44	3,160	7.6	30,589	0.4	248	41,828	413,601
45-64	11,615	23.3	123,732	0.4	46	3,063	6.1	31,443	0.4	286	49,842	461,435
65-74	29	21.2	185	0.5	45	7	5.1	36	0.3	170	137	602
75-84	1	10.0	3	0.3	3	0	0.0	0	0.0	0	10	65
85 and older	2	66.7	24	0.4	16	0	0.0	0	0.0	0	3	27

### TABLE ND.7D MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR NINTH AND TENTH TOP DRUG GROUPS

### SEPARATELY, BY SEX, BASIS OF ELIGIBILITY, AND AGE<sup>a, b, c</sup> NONDUAL BENEFICIARIES, TEXAS, 2005

		UL	CER DRUGS					ANTIVIRAL				
		Users	Number of Benefit N	Mean lumber of	Mean		Users	Number of Benefit N	Mean lumber of	Mean		
		as %			Rx \$ per		as %			Rx \$ per		
Beneficiary	Number of	of All	Among	Benefit	Benefit	Number of	of All	Among	Benefit	Benefit	Number of	Number of
Characteristics	Users	Benes	Users	Month	Month	Users	Benes	Users	Month	Month	Beneficiaries E	Benefit Months
Male, Other Elig	ibles											
All Ages	52,532	4.1	473,307	0.2	13	27,949	2.2	277,665	0.1	12	1,293,588	9,470,925
5 and younger	24,167	4.0	208,424	0.2	9	13,050	2.2	131,826	0.1	5	606,591	4,441,251
6-14	16,550	3.4	160,767	0.2	11	11,429	2.4	114,519	0.1	10	484,929	3,666,799
15-20	6,967	4.4	65,245	0.2	15	2,800	1.8	26,685	0.1	12	159,475	1,132,517
21-44	2,762	9.0	20,871	0.3	35	461	1.5	3,136	0.3	229	30,711	156,940
45-64	1,368	14.2	10,481	0.3	41	185	1.9	1,245	0.4	376	9,629	52,252
65-74	300	30.2	3,137	0.4	40	13	1.3	126	0.2	187	995	9,114
75-84	259	31.1	2,788	0.5	47	7	0.8	84	0.1	6	832	8,112
85 and older	159	37.3	1,594	0.5	51	4	0.9	44	0.1	7	426	3,940
Unknown	3	4.8	35	0.5	49	0	0.0	0	0.0	0	62	335

Source: Data for this table are from the MAX 2005 file for Texas, released by CMS in 10/2008. This table was produced on 04/23/2009.

a. Table ND.7D includes the beneficiaries represented by Cell K of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2005. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2005. For information about these drug groups, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription (s) or pharmacy; \$ = Medicaid reimbursement.

### TABLE ND.8 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS, BY BENEFICIARY CHARACTERISTIC<sup>a, b</sup> NONDUAL BENEFICIARIES, TEXAS, 2005

Beneficiary		Number of Dy per Penefit	Number of All-Year Nursing	Benefit Months Among All- Year Nursing Facility
Characteristics	Rx \$ per Benefit Month	Month	•	Residents
All	\$600	8.2	,	51,688
Age				
0-64	640	8.5	3,835	40,540
65-74	563	7.7	272	2,760
75-84	448	7.1	402	3,962
85 and older	387	6.5	454	4,426
Unknown	0	0.0	0	0
Gender				
Female	625	8.6	2,731	28,820
Male	568	7.7	2,229	22,833
Unknown	504	8.1	3	35
Race				
White	618	8.5	2,586	26,426
African American	574	7.8	1,078	11,464
Other/unknown	587	8	1,299	13,798
Basis of Eligibility	:			
Aged	449	7.0	1,108	11,052
Disabled	641	8.5	3,846	40,576
Adults	495	10.0	8	56
Children	81	0.8	1	4
Unknown	0	0.0	0	0

Source: Data for this table are from the MAX 2005 file for Texas, released by CMS in 10/2008. This table was produced on 04/23/2009.
a. Table ND.8 includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their 2005 Medicaid enrollment. A total of 4,187 beneficiaries who were in nursing facilities for part of their enrollment and their 40,113 benefit months were excluded from the analysis. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability

or blindness. The children's group includes children receiving foster care and adoptive services.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy; \$ = Medicaid reimbursement.

### TABLE ND.9 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS,

### BY BRAND STATUS AND THERAPEUTIC CATEGORY<sup>a, b, c, d, e</sup> NONDUAL BENEFICIARIES, TEXAS, 2005

Number of Rx per Benefit \$ per Benefit Month Among

Month Among Users Users \$ per Rx Users

Therapeutic Category	P Total	atented Brand- Name	Off- Patent Brand- Name G	Generic		atented Brand- Name		Generic		Patented Brand- Name	Off- Patent Brand- Name (		Total Number of Rx	Total Rx \$	Number of Users	As a Percentage of All-Year Nursing Facility Residents	Number of Benefit Months
Anti-infective Agents	0.4	0.1	0.0	0.2	\$40	\$27	\$5	\$7	\$97	\$214	\$125	\$30	15,411	\$1,492,158	3,437	69.3	37,577
Biologicals	0.0	0.0	0.0	0.0	0	0	0	0	0	0	0	0	0	0	0	0.0	0
Antineoplastic Agents	0.5	0.0	0.0	0.4	71	14	0	57	156	360	140	137	1,824	284,626	387	7.8	4,012
Endocrine/Metabolic Drugs	1.3	0.5	0.2	0.6	68	48	7	12	52	97	45	19	34,762	1,823,145	2,475	49.9	26,865
Cardiovascular Agents	2.1	0.7	0.0	1.4	84	61	0	23	40	82	75	17	78,999	3,128,881	3,483	70.2	37,193
Respiratory Agents	0.7	0.3	0.0	0.4	40	32	1	7	53	103	45	16	21,622	1,151,665	2,690	54.2	29,106
Gastrointestinal Agents	1.2	0.5	0.0	0.6	80	66	2	12	69	128	99	19	40,334	2,783,014	3,217	64.8	34,651
Genitourinary Agents	0.6	0.4	0.0	0.2	42	34	1	8	70	87	76	38	7,740	545,368	1,169	23.6	12,914
CNS Drugs	2.0	1.1	0.0	0.8	224	203	1	21	114	178	60	25	86,189	9,826,348	4,049	81.6	43,829
Stimulants/Anti-obesity/Anorexia	0.6	0.4	0.0	0.2	80	74	0	7	128	178	0	31	443	56,546	65	1.3	703
Miscellaneous Psychological/ Neurological Agents	0.9	0.9	0.0	0.0	165	163	0	2	177	178	69	131	7,596	1,344,403	760	15.3	8,164
Analgesics and Anesthetics	1.0	0.2	0.0	0.8	59	30	12	17	57	140	290	22	32,020	1,817,024	2,869	57.8	30,935
Neuromuscular Agents	1.5	0.4	0.0	1.1	113	64	3	45	76	163	116	43	46,429	3,540,040	2,842	57.3	31,451
Nutritional Products	0.7	0.0	0.0	0.7	12	1	0	11	17	27	45	16	12,008	203,215	1,558	31.4	16,873
Hematological Agents	0.9	0.4	0.0	0.5	104	96	0	8	110	235	42	14	16,845	1,854,776	1,685	34.0	17,866
Topical Products	0.6	0.3	0.0	0.2	31	22	3	6	53	75	64	25	19,746	1,048,001	3,046	61.4	33,789
Miscellaneous Products	0.3	0.1	0.0	0.2	22	15	0	6	76	269	188	27	1,191	90,878	380	7.7	4,205
Unknown Therapeutic Category	0.3	0.0	0.0	0.0	9	0	0	0	30	0	0	0	476	14,378	144	2.9	1,643
TOTAL NO. OF RX AND RX \$	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	423,635	31,004,466	n.a.	n.a.	n.a.

a. Table ND.9 includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2005. A total of 4,187 beneficiaries who were

in nursing facilities for part of their enrollment and their 40,113 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given therapeutic category during 2005. A beneficiary who used drugs from two or more categories was counted as a user for each category. Therefore, the sum of users across categories may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

d. For information about these therapeutic categories, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615

e. Brand-name drugs, sometimes called "innovator single-source drugs," are drugs whose patents have not yet expired. Off-patent brand-name drugs, sometimes called "innovator multiple-source drugs," are brand-name drugs whose patents have expired. Generic drugs, sometimes called "non-innovator multiple-source drugs," are off-patent drugs manufactured and sold by companies other than the original patent holder. For information about this classification method, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

In Texas, 0.7 percent of drug claims have missing values for brand status. Thus, the sum of the three groups in this table may be smaller than all prescriptions combined.

Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; CNS = Central Nervous System; MAX = Medicaid Analytic Extract; n.a. = not applicable; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

### TABLE ND.10 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR TOP 10 DRUG GROUPS AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY TOP-10 DRUG GROUP<sup>a, b, c, d</sup>

### NONDUAL BENEFICIARIES, TEXAS, 2005

			Users				Among Users
Top 10 Drug Groups in Nursing Facilities	Total Medicaid Rx \$	Number of Users	As a Percentage of All-Year Nursing Facility Residents	Number of Benefit Monthsp	Number of Rx er Benefit Month	\$ per Rx	Rx \$ per Benefit Month
ANTIPSYCHOTICS	\$7,046,093	3,403	68.6	38,195	0.8	\$227	\$184
ANTICONVULSANT	3,048,692	3,315	66.8	37,004	0.9	88	82
ULCER DRUGS	2,238,899	3,175	64.0	34,333	0.7	89	65
ANTIDEPRESSANTS	2,179,551	3,868	77.9	42,582	0.8	66	51
ANTIDIABETIC	1,501,100	2,918	58.8	31,919	0.9	51	47
MISC PSYCHOTHERAPEUTIC AND NEUROLOGICAL	1,344,403	959	19.3	10,285	0.7	177	131
ANTIHYPERLIPIDEMIC	1,254,251	1,469	29.6	16,319	0.7	104	77
ANALGESICS - Narcotic	932,923	3,065	61.8	32,773	0.7	43	28
HEMATOPOIETIC AGENTS	852,253	675	13.6	7,168	0.7	182	119
ANTIASTHMATIC	816,429	2,805	56.5	30,188	0.4	63	27
Total	21,214,594	25,652		280,766	n.a.	n.a.	n.a.

Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$= Medicaid reimbursement.

Source: Data for this table are from the MAX 2005 file for Texas, released by CMS in 10/2008. This table was produced on 04/23/2009.

a. Table ND.10 includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2005. A total of 4,187 beneficiaries who were in nursing facilities for part of their enrollment and their 40,113 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2005. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. wedicald relinious/serient and action of the control of the con

### TABLE ND.10A

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR TOP 10 DRUG GROUPS COMBINED AND FIRST AND SECOND TOP DRUG GROUPS SEPARATELY AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY SEX, BASIS OF ELIGIBILITY, AND AGE<sup>a, b, c, d</sup> NONDUAL BENEFICIARIES, TEXAS, 2005

	All Top 10	Drug Groups		ANTIPS	YCHOTICS				ANTICO	NVULSANT		
Beneficiary Characteristics	Number of Rx	Rx \$	Number of Users	Users as % of All-Year Nursing Facility Residents	Benefit Months Among	Mean Number of Rx		Number of Users	Users as % of All-Year Nursing Facility Residents	Benefit Months Among	Mean Number of Rx	
All	212,236	\$21,214,594	3,403	68.6	38,195	0.8	\$185	3,315	66.8	37,004	0.9	\$82
Female												
All Females	123,168	12,602,459	1,929	70.6	21,811	0.8	187	1,833	67.1	20,716	0.9	85
Female, Disabled												
All Ages	99,326	10,396,360	1,514	76.9	17,307	0.9	200	1,601	81.3	18,154	0.9	89
64 or younger	98,965	10,332,121	1,510	77.3	17,291	0.9	200	1,591	81.5	18,099	0.9	89
65-74	361	64,239	4	23.5	16	1.1	251	10	58.8	55	1.0	49
75-84	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
85 and older	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
Female, Other Eligibles												
All Ages	23,842	2,206,099	415	54.5	4,504	0.7	136	232	30.5	2,562	0.8	52
64 or younger	123	8,090	4	66.7	48	0.4	46	3	50.0	36	1.0	41
65-74	6,432	644,575	111	76.6	1,272	0.9	194	96	66.2	1,107	0.9	60
75-84	8,492	756,793	156	57.6	1,655	0.7	114	78	28.8	869	0.8	49
85 and older	8,795	796,641	144	42.5	1,529	0.7	114	55	16.2	550	0.8	43
Male												
All Males	88,930	8,599,433	1,469	65.9	16,325	0.8	182	1,480	66.4	16,264	0.9	80
Male, Disabled												
All Ages	78,126	7,597,077	1,274	67.9	14,229	0.8	187	1,362	72.6	15,020	0.9	82
64 or younger	77,854	7,576,940	1,268	67.9	14,194	0.8	187	1,359	72.8	14,997	0.9	82
65-74	272	20,137	6	66.7	35	0.7	161	3	33.3	23	0.8	39
75-84	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
85 and older	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
Male, Other Eligibles												
All Ages	10,804	1,002,356	195	55.2	2,096	0.8	146	118	33.4	1,244	0.8	56
64 or younger	248	21,661	5	55.6	28	0.6	237	4	44.4	39	1.2	100
65-74	3,817	343,880	72	71.3	799	0.9	172	46	45.5	511	0.9	55
75-84	3,976	383,926	74	57.4	805	0.7	134	42	32.6	424	0.7	68
85 and older	2,763	252,889	44	38.6	464	0.8	114	26	22.8	270	0.7	34
Unknown	138	12,702	5	166.7	59	0.4	70	2	66.7	24	0.5	33

a. Table ND.10A includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2005. A total of 4,187 beneficiaries who were in nursing facilities for part of their enrollment and their 40,113 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2005. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

d. The top 10 drug groups were determined based on total 2005 Medicaid reimbursement for all-year nursing facility residents in this state. For information about these drug groups, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentld=09e014-680a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

### TABLE ND.10B

### MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR THIRD TO FIFTH TOP DRUG GROUPS SEPARATELY

AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY SEX, BASIS OF ELIGIBILITY, AND AGEA, b, c, d

NONDUAL BENEFICIARIES, TEXAS, 2005

	ULCER DRUGS					INDOAL BLINE		RESSANTS	3			ANTIE	DIABETIC		
Beneficiary Characteristics	Number of Users	Year Nursing Facility	Number of Benefit Months Among Users	Mean Number of Rx		Number of Users	Users as % of All- Year Nursing Facility Residents	Number of Benefit Months Among Users			Number of Users	Users as % of All- Year Nursing Facility Residents	Number of Benefit Months Among Users	Mean Number of Rx	
All	3,175	64.0	34,333	0.7		3,868	77.9	42,582			2,918	58.8	31,919	0.9	
Female															
All Females	1,714	62.8	18,807	0.7	67	2,261	82.8	25,022	0.8	54	1,716	62.8	18,999	0.9	48
Female, Disable	ed														
All Ages	1,292	65.6	14,368	0.8	68	1,736	88.1	19,313	0.8	56	1,319	67.0	14,774	0.9	49
64 or younger	1,285	65.8	14,335	0.8	68	1,724	88.3	19,231	0.8	56	1,314	67.3	14,747	0.9	49
65-74	7	41.2	33	0.8	72	12	70.6	82	0.6	34	5	29.4	27	1.0	81
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
85 and older	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
Female, Other E	Eligibles														
All Ages	422	55.5	4,439	0.7	62	525	69.0	5,709	0.7	48	397	52.2	4,225	0.9	43
64 or younger	4	66.7	30	0.4	22	2	33.3	24	0.9	37	5	83.3	28	0.4	. 8
65-74	88	60.7	1,005	0.7	65	118	81.4	1,360	0.7	50	109	75.2	1,229	0.9	48
75-84	148	54.6	1,543	0.7	59	196	72.3	2,116	0.7	48	144	53.1	1,510	0.9	46
85 and older	182	53.7	1,861	0.7	65	209	61.7	2,209	0.7	48	139	41.0	1,458	0.8	35
Male															
All Males	1,459	65.5	15,502	0.7	63	1,602	71.9	17,501	0.8	47	1,202	53.9	12,920	0.9	46
Male, Disabled															
All Ages	1,256	67.0	13,389	0.7	65	1,389	74.0	15,218	0.8	48	1,022	54.5	11,062	0.9	47
64 or younger	1,253	67.1	13,373	0.7	65	1,380	73.9	15,159	0.8	48	1,014	54.3	10,996	0.9	47
65-74	3	33.3	16	0.9	72	9	100.0	59	1.0	35	8	88.9	66	0.9	33
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
85 and older	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
Male, Other Elig	jibles														
All Ages	203	57.5	2,113	0.7	56	213	60.3	2,283	0.7	42	180	51.0	1,858	0.9	42
64 or younger	6	66.7	38	0.9	89	4	44.4	23	0.8	70	6	66.7	27	0.9	89
65-74	58	57.4	643	0.7	46	61	60.4	687	0.8	41	68	67.3	717	0.9	42
75-84	78	60.5	820	0.7	60	84	65.1	901	0.7	45	70	54.3	752	0.8	39
85 and older	61	53.5	612	0.7	59	64	56.1	672	0.7	38	36	31.6	362	0.8	45
Unknown	2	66.7	24	0.4	33	5	166.7	59	0.6	38	0	0.0	0	0.0	0

a. Table ND.10B includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2005. A total of 4,187 beneficiaries who were in nursing facilities for part of their enrollment and their 40,113 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2005. A beneficiary who used drugs from two or more drug groups was counted as a user for each

group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

d. The top 10 drug groups were determined based on total 2005 Medicaid reimbursement for all-year nursing facility residents in this state. For information about these drug groups, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

### TABLE ND.10C

### MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR SIXTH TO EIGHTH TOP DRUG GROUPS SEPARATELY AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY SEX, BASIS OF ELIGIBILITY, AND AGEA, b, c, d

NONDUAL BENEFICIARIES, TEXAS, 2005

	MISC		HERAPEUT OLOGICAL	IC AND			ANTIHYP	ERLIPIDEMI	С			ANALGES	ICS - Narcoti	ic	
Beneficiary Characteristics	Number of Users	Users as % of All- Year Nursing Facility Residents	Number of Benefit Months Among Users	Mean Number of Rx		Number of Users	Users as % of All- Year Nursing Facility Residents	Number of Benefit Months Among Users			Number of Users	Users as % of All- Year Nursing Facility Residents	Number of Benefit Months Among I Users	Mean Number of Rx	
All	959	19.3	10,285	0.7	\$131	1,469	29.6	16,319	0.7	\$77	3,065	61.8	32,773	0.7	\$29
Female															
All Females	605	22.2	6,504	0.7	143	859	31.5	9,593	0.7	78	1,798	65.8	19,616	0.6	29
Female, Disable	ed														
All Ages	308	15.6	3,385	0.7	176	676	34.3	7,618	0.8	78	1,439	73.0	15,800	0.7	32
64 or younger	304	15.6	3,353	0.7	176	671	34.4	7,590	0.8	78	1,428	73.1	15,745	0.7	32
65-74	4	23.5	32	0.8	110	5	29.4	28	0.7	75	11	64.7	55	1.8	167
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	C
85 and older	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	C
Female, Other E	Eligibles														
All Ages	297	39.0	3,119	0.8	108	183	24.0	1,975	0.7	75	359	47.2	3,816	0.5	15
64 or younger	0	0.0	0	0.0	0	0	0.0	0	0.0	0	4	66.7	39	0.2	4
65-74	35	24.1	395	0.8	113	57	39.3	667	0.7	75	69	47.6	755	0.4	11
75-84	105	38.7	1,067	0.7	99	78	28.8	798	0.8	77	128	47.2	1,381	0.5	21
85 and older	157	46.3	1,657	0.8	112	48	14.2	510	0.7	71	158	46.6	1,641	0.4	12
Male															
All Males	351	15.7	3,746	0.7	110	609	27.3	6,714	0.7	76	1,264	56.7	13,123	0.7	28
Male, Disabled															
All Ages	226	12.0	2,414	0.7	112	528	28.1	5,868	0.7	76	1,102	58.7	11,446	0.7	30
64 or younger	226	12.1	2,414	0.7	112	526	28.2	5,859	0.7	76	1,097	58.8	11,406	0.7	30
65-74	0	0.0	0	0.0	0	2	22.2	9	1.2	123	5	55.6	40	0.9	37
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	C
85 and older	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	(
Male, Other Elig	jibles														
All Ages	125	35.4	1,332	0.7	105	81	22.9	846	0.7	72	162	45.9	1,677	0.5	13
64 or younger	2	22.2	16	0.7	107	2	22.2	11	0.6	77	4	44.4	21	0.7	12
65-74	23	22.8	252	0.8	106	30	29.7	327	0.8	78	53	52.5	588	0.6	16
75-84	49	38.0	516	0.7	104	36	27.9	366	0.7	74	58	45.0	595	0.5	8
85 and older	51	44.7	548	0.8	104	13	11.4	142	0.5	55	47	41.2	473	0.4	16
Unknown	3	100.0	35	0.8	107	1	33.3	12	1.0	77	3	100.0	34	0.5	3

Source: Data for this table are from the MAX 2005 file for Texas, released by CMS in 10/2008. This table was produced on 04/23/2009.

Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

a. Table ND.10C includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2005. A total of 4,187 beneficiaries who were

in nursing facilities for part of their enrollment and their 40,113 benefit months were excluded from the analysis.

In full stag ractifies for part of their entiremental and trief and 1/13 benefit informs were excluded from the analysis.

A user is a beneficiary who had at least one prescription filled in a given drug group during 2005. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

d. The top 10 drug groups were determined based on total 2005 Medicaid reimbursement for all-year nursing facility residents in this state. For information about these drug groups, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

### TABLE ND.10D

## MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR NINTH AND TENTH TOP DRUG GROUPS SEPARATELY AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY SEX, BASIS OF ELIGIBILITY, AND AGE $^a$ , $^b$ , $^c$ , $^d$

NONDUAL BENEFICIARIES, TEXAS, 2005

HEMATOPOIETIC AGENTS

ANTIASTHMATIC

Beneficiary Characteristics	Number of Users	Users as % of All-Year Nursing Facility Residents	Number of Benefit Months Among Users	Mean Number of Rx	Mean Rx \$	Number of Users	Users as % of All-Year Nursing Facility Residents	Number of Benefit Months Among I Users	Mean Number of Rx	Mean Rx \$	All-Year Nursing Facility Residents	Benefit Months Among All- Year Nursing Facility Residents
All	675	13.6	7,168	0.7	\$119	2,805	56.5	30,188	0.4	\$27	4,963	51,688
Female												
All Females	325	11.9	3,515	0.6	155	1,651	60.5	17,924	0.4	26	2,731	28,820
Female, Disable	d											
All Ages	252	12.8	2,748	0.6	157	1,268	64.4	13,962	0.4	28	1,970	21,250
64 or younger	249	12.7	2,729	0.6	145	1,260	64.5	13,919	0.4	28	1,953	21,167
65-74	3	17.6	19	1.0	1,806	8	47.1	43	0.5	24	17	83
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0
85 and older	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0
Female, Other E	ligibles											
All Ages	73	9.6	767	0.6	149	383	50.3	3,962	0.3	19	761	7,570
64 or younger	1	16.7	3	0.3	691	4	66.7	23	0.6	19	6	47
65-74	9	6.2	98	0.7	177	89	61.4	969	0.3	20	145	1,572
75-84	34	12.5	353	0.6	136	110	40.6	1,131	0.4	19	271	2,652
85 and older	29	8.6	313	0.6	149	180	53.1	1,839	0.3	19	339	3,299
Male												
All Males	350	15.7	3,653	0.7	84	1,154	51.8	12,264	0.5	28	2,229	22,833
Male, Disabled												
All Ages	294	15.7	3,073	0.7	76	970	51.7	10,390	0.5	30	1,876	19,326
64 or younger	291	15.6	3,063	0.7	74	964	51.6	10,358	0.5	30	1,867	19,277
65-74	3	33.3	10	1.4	390	6	66.7	32	1.1	55	9	49
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0
85 and older	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0
Male, Other Elig	ibles											
All Ages	56	15.9	580	0.7	130	184	52.1	1,874	0.3	20	353	3,507
64 or younger	1	11.1	12	1.0	7	6	66.7	38	1.6	22	9	49
65-74	18	17.8	203	0.7	109	35	34.7	403	0.3	18	101	1,056
75-84	15	11.6	141	0.7	174	72	55.8	742	0.4	24	129	1,286
85 and older	22	19.3	224	0.6	128	71	62.3	691	0.3	17	114	1,116
Unknown	0	0.0	0	0.0	0	0	0.0	0	0.0	0	3	35

a. Table ND.10D includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2005. A total of 4,187 beneficiaries who were in nursing facilities for part of their enrollment and their 40,113 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2005. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

d. The top 10 drug groups were determined based on total 2005 Medicaid reimbursement for all-year nursing facility residents in this state. For information about these drug groups, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

### TABLE ND.11 USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D AMONG NONDUALS, BY BENEFICIARY CHARACTERISTICa,b TEXAS, 2005

Beneficiary Characteristics	Number of Beneficiaries with at Least One Part D Excluded Rx	Percentage of Beneficiaries with at Least One Part D Excluded Rx	Number of Part D Excluded Rx per Beneficiary	Total Number Part D Excluded Rx	\$ per	Total Part D Excluded Rx \$		Part D Excluded Rx \$ as a 'ercentage of All Nondual Rx \$	Total Number of Beneficiaries
All	1,461,307	44.9	1.7	5,442,565	\$26	\$83,571,071	\$15	6.1	3,253,138
Age									
5 and younger	711,377	58.9	2.6	3,190,893	34	41,253,596	13	16.0	1,208,235
6-14	421,327	41.5	1.2	1,205,648	21	21,302,019	18	6.2	1,016,455
15-20	129,393	30.5	0.7	308,152	14	6,141,774	20	3.9	424,543
21-44	134,417	30.2	0.9	394,279	17	7,698,666	20	2.7	445,003
45-64	62,134	40.8	2.2	329,645	45	6,932,570	21	2.2	152,412
65-74	1,116	38.2	1.8	5,278	34	100,145	19	1.9	2,921
75-84	881	41.9	2.3	4,771	40	84,250	18	1.9	2,105
85 and older	662	45.3	2.7	3,899	40	58,051	15	1.8	1,462
Unknown	0	0.0	0.0	0	0	0	0	0.0	2
Basis of Eligibility	С								
Aged	2,529	41.5	2.2	13,590	39	235,716	17	1.9	6,097
Disabled	138,161	43.5	2.3	714,375	52	16,557,691	23	2.5	317,269
Adults	130,411	28.1	0.6	278,912	9	4,406,484	16	3.4	464,232
Children	1,190,153	48.3	1.8	4,435,583	25	62,369,581	14	10.9	2,464,995
Unknown	53	9.7	0.2	105	3	1,599	15	2.1	545
Gender									
Female	794,103	44.1	1.6	2,868,830	25	44,663,286	16	6.0	1,799,707
Male	667,196	45.9	1.8	2,573,684	27	38,907,102	15	6.1	1,453,371
Unknown	8	13.3	0.9	51	11	683	13	2.3	60
Race									
White	275,182	36.9	1.1	799,139	21	15,406,551	19	3.3	745,226
African American	196,482	31.6	0.9	544,736	14	8,743,549	16	3.6	622,725
Other/unknown	989,643	52.5	2.2	4,098,690	32	59,420,971	14	8.9	1,885,187
Use of Nursing Fac	cilitiesd								
Entire year	3,252	65.5	7.0	34,508	117	581,685	17	1.9	4,963
Part year	2,866	68.5	5.0	20,757	91	379,713	18	2.1	4,187
None	1,455,189	44.9	1.7	5,387,300	25	82,609,673	15	6.2	3,243,988
Maintenance Assis	stance Status								
Cash	251,610	44.7	2.2	1,217,581	42	23,619,603	19	3.3	562,480
Medically needy	24,902	30.2	0.8	65,057	15	1,218,442	19	3.3	82,563
Poverty related	1,006,231	45.6	1.6	3,501,149	23	50,003,021	14	10.6	2,207,857
Other/unknown	178,564	44.6	1.6	658,778	22	8,730,005	13	6.1	400,238

Source: Data for this table are from the MAX 2005 file for Texas, released by CMS in 10/2008. This table was produced on 04/23/2009.

a. Table ND.11 includes the beneficiaries represented by Cell K of Table 1. Beneficiaries include all nondual Medicaid beneficiaries who had Medicaid pharmacy benefits during at least one month

b. The statute establishing the Medicare Part D prescription program that started in 2006 excludes several types of drugs from coverage. State Medicaid programs have been allowed to exclude these drugs since 1990, but many states have chosen to cover them, and if states cover them for any Medicaid beneficiaries they must also cover them for dual eligibles, who as of 2006 receive the remainder of their prescription drug coverage through Part D. Excluded drugs include benzodiazepines; barbiturates; nonprescription (OTC) medications; prescription vitamins and minerals (not including prenatal vitamins and fluoride preparations); and drugs used for anorexia, weight loss, or weight gain. Other excluded drugs include those that promote fertility; those used for cosmetic purposes or hair growth, for symptomatic relief of coughs and colds; or drugs for which the manufacturer requires that associated tests or monitoring services be purchased exclusively from

c. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.

d. Please refer to footnote f on Table 1 for methodology used to determine use of nursing facilities.

Bene(s) = beneficiary (or beneficiaries); CMS = Centers for Medicare & Medicaid Services; Excl = excluded; MAX = Medicaid Analytic Extract; OTC = over-the-counter; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

# TABLE ND.12 USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D AMONG NONDUALS PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC<sup>a,b</sup> TEXAS. 2005

Beneficiary Maracteristics	Number Rx per Benefit Month	Rx \$ per Benefit Month	\$ per Rx	Barbiturate \$ per Benefit Month	Benzodiazepine \$ per Benefit Month	Number of Benefit Months
All	0.2	\$4	\$15	\$0	\$0	23,839,465
Age						
5 and younger	0.4	5	13	0	0	8,896,395
6-14	0.2	3	18	0	0	7,847,523
15-20	0.1	2	20	0	0	2,990,832
21-44	0.1	3	20	0	1	2,687,799
45-64	0.2	5	21	0	2	1,357,366
65-74	0.2	4	19	0	1	25,741
75-84	0.2	4	18	0	1	20,202
85 and older	0.3	4	15	0	1	13,604
Unknown	0.0	0	0	0	0	3
Basis of Eligibility <sup>c</sup>						
Aged	0.2	4	17	0	1	57,485
Disabled	0.2	5	23	0	2	3,169,699
Adults	0.1	2	16	0	0	2,366,128
Children	0.2	3	14	0	0	18,242,420
Unknown	0.0	0	15	0	0	3,733
Gender						
Female	0.2	3	16	0	0	12,788,819
Male	0.2	4	15	0	0	11,050,314
Unknown	0.2	2	13	0	1	332
Race						
White	0.1	3	19	0	1	5,432,441
African American	0.1	2	16	0	0	4,205,557
Other/unknown	0.3	4	14	0	0	14,201,467
Use of Nursing Facil	ities <sup>d</sup>					
Entire year	0.7	11	17	0	6	51,688
Part year	0.5	9	18	0	5	40,113
None	0.2	3	15	0	0	23,747,664
Maintenance Assista	nce Status					
Cash	0.2	5	19	0	2	4,902,500
Medically needy	0.1	2	19	0	1	538,540
Poverty related	0.2	3	14	0	0	15,651,377
Other/unknown	0.2	3	13	0	0	2,747,048

a. Table ND.12 includes the beneficiaries represented by Cell K of Table 1. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits. Beneficiaries include all nondual Medicaid beneficiaries who had Medicaid pharmacy benefits during at least one month in 2005.

b. The statute establishing the Medicare Part D prescription program that started in 2006 excludes several types of drugs from coverage. State Medicaid programs have been allowed to exclude these drugs since 1990, but many states have chosen to cover them, and if states cover them for any Medicaid beneficiaries they must also cover them for dual eligibles, who as of 2006 receive the remainder of their prescription drug coverage through Part D. Excluded drugs include they barbiturates; nonprescription (OTC) medications; prescription vitamins and minerals (not including prenatal vitamins and fluoride preparations); and drugs used for anorexia, weight loss, or weight gain. Other excluded drugs include those that promote fertility; those used for cosmetic purposes or hair growth, for symptomatic relief of coughs and colds; or drugs for which the manufacturer requires that associated tests or monitoring services be purchased exclusively from the manufacturer.

c. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficaries of any age who were determined to be eligible because of disability

or blindness. The children's group includes children receiving foster care and adoptive services.

d. Please refer to footnote f on Table 1 for methodology used to determine use of nursing facilities.

TABLE ND.13
USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D FOR SELECTED DRUG CATEGORIES AMONG NONDUALS $^{a,b,c}$  TEXAS, 2005

Drug Category	Number of Users	Rx \$ per User	Total Rx \$	Rx \$ as a Percentage of All Part D Excluded Rx \$	Total Number Rx.	\$ per Rx	Number Rx as a Percentage of All Part D Excluded Rx
All	2,137,140	\$39	\$83,571,071	100.0	5,442,565	\$15	100.0
Anorexia or weight loss/gain	0	0	0	0.0	0	0	0.0
Fertility drugs	26	71	1,854	0.0	28	66	0.0
Drugs for cosmetic purposes	658	17	11,393	0.0	895	13	0.0
Cough and cold medications	1,045,849	43	44,665,762	53.4	2,161,778	21	39.7
Vitamins and minerals	119,765	25	2,994,990	3.6	234,180	13	4.3
Non-prescription drugs	859,934	28	24,140,028	28.9	2,604,683	9	47.9
Barbiturates	5,402	55	297,909	0.4	34,738	9	0.6
Benzodiazepines	82,043	116	9,550,451	11.4	366,770	26	6.7
Other Part D Excl Rx Drugs	23,463	81	1,908,684	2.3	39,493	48	0.7

Bene(s) = beneficiary (or beneficiaries); CMS = Centers for Medicare & Medicaid Services; Excl = excluded; MAX = Medicaid Analytic Extract; OTC = over-the-counter; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

a. Table ND.13 includes the beneficaries represented by Cell K of Table 1. Beneficiaries include all nondual Medicaid beneficiaries who had Medicaid pharmacy benefits during at least one month in 2005. A user is a beneficiary who had at least one prescription filled for a Part D excluded drug in 2005. A beneficiary who sused drugs from two or more Part D excluded categories was counted as a user for each category. Therefore, the sum of users across drug categories may exceed the total number of individual users as noted on Table ND11.

b. Includes OTC drugs as well as prescription drugs.

c. The statute establishing the Medicare Part D prescription program that started in 2006 excludes several types of drugs from coverage. State Medicaid programs have been allowed to exclude these drugs since 1990, but many states have chosen to cover them, and if states cover them for any Medicaid beneficiaries they must also cover them for dual eligibles, who as of 2006 receive the remainder of their prescription drug coverage through Part D. Excluded drugs include benzodiazepines; barbiturates; nonprescription (OTC) medications; prescription strains and similar in a state of the prescription of the prescription of the prescription strains in a state of the prescription strains and similar in a state of the prescription strains and strains and fluoride preparations); and drugs used for anorexia, weight loss, or weight gain. Other excluded drugs include those that promote fertility; those used for cosmetic purposes or hair growth, for symptomatic relief of coughs and colds; or drugs for which the manufacturer requires that associated tests or monitoring services be purchased exclusively from the manufacturer.

APPENDIX TABLE A.1 CHARACTERISTICS OF MEDICAID BENEFICIARIES WITH AT LEAST ONE MONTH OF PHARMACY BENEFIT COVERAGE, BY BASIS OF ELIGIBILITY<sup>a, b</sup> NONDUAL BENEFICIARIES, TEXAS, 2005

			Number of			FICIARIES, TEXAS,	2000		Number of	Benefit Mon	ths	
Beneficiary Characteristics	All	Aged	Blind/ Disabled	Adults	Children	Other/ Unknown	All	Aged	Blind/ Disabled	Adults	Children	Other/ Unknown
All	3,425,751	6,180	322,318	478,164	2,618,530	559	29,704,067	59,536	3,357,024	2,937,739	23,345,744	4,024
Age												
5 and younger	1,276,867	1	20,437	9	1,256,420	0	11,283,418	4	214,586	41	11,068,787	0
6-14	1,079,388	0	54,058	337	1,024,993	0	9,990,543	0	599,876	2,203	9,388,464	0
15-20	450,788	0	34,498	79,304	336,984	2	3,765,792	0	371,422	506,660	2,887,698	12
21-44	458,045	5	89,565	368,038	118	319	3,173,653	42	932,185	2,238,489	720	2,217
45-64	154,079	45	123,389	30,402	12	231	1,428,969	284	1,237,073	189,789	68	1,755
65-74	2,975	2,590	316	63	0	6	27,157	25,025	1,599	496	0	37
75-84	2,134	2,088	38	8	0	0	20,792	20,563	186	43	0	0
85 and older	1,472	1,451	17	3	1	0	13,737	13,618	97	18	4	0
Unknown	3	0	0	0	2	1	6	0	0	0	3	3
Gender												
Female	1,889,407	3,893	159,375	434,921	1,290,660	558	15,939,241	37,551	1,675,965	2,694,570	11,527,134	4,021
Male	1,536,282	2,281	162,940	43,241	1,327,820	0	13,764,481	21,918	1,681,053	243,165	11,818,345	0
Unknown	62	6	3	2	50	1	345	67	6	4	265	3
Race												
White	778,390	2,042	98,683	139,494	537,885	286	6,453,007	19,384	1,026,664	851,387	4,553,548	2,024
African American	667,267	1,248	87,082	112,787	466,061	89	5,657,214	11,914	891,866	663,150	4,089,608	676
Other/unknown	1,980,094	2,890	136,553	225,883	1,614,584	184	17,593,846	28,238	1,438,494	1,423,202	14,702,588	1,324
Use of Nursing Facilities <sup>c</sup>												
Entire year	4,963	1,108	3,846	8	1	0	51,753	11,053	40,640	56	4	0
Part year	4,187	529	3,601	47	8	2	41,656	4,947	36,256	363	70	20
None	3,416,601	4,543	314,871	478,109	2,618,521	557	29,610,658	43,536	3,280,128	2,937,320	23,345,670	4,004
Maintenance Assistance Statu	ıs											
Cash	578,638	3,992	315,184	79,944	179,518	0	5,622,010	40,362	3,289,300	508,195	1,784,153	0
Medically needy	82,563	0	0	82,037	526	0	554,340	0	0	551,744	2,596	0
Poverty related	2,324,538	25	31	247,994	2,075,929	559	20,300,119	255	294	1,432,799	18,862,747	4,024
Other/unknown	440,012	2,163	7,103	68,189	362,557	0	3,227,598	18,919	67,430	445,001	2,696,248	0
Managed Care (MC) Status												
Fee-for-service (FFS) all year	2,067,771	5,334	260,522	315,991	1,485,387	537	17,566,297	50,426	2,662,103	1,858,796	12,991,114	3,858
FFS part year, with Rx claims	532,640	189	18,114	87,010	427,321	6	5,051,074	1,807	197,195	668,654	4,183,358	60
FFS part year, no Rx claims	239,823	30	3,025	20,224	216,542	2	1,905,975	260	28,351	109,377	1,767,971	16
MC all year, with Rx claims	412,904	544	35,608	41,007	335,745	0	4,052,912	6,314	414,994	252,105	3,379,499	0
MC all year, no Rx claims	172,599	83	5,049	13,932	153,535	0	1,127,719	729	54,381	48,807	1,023,802	0

a. Table A.1 includes the beneficiaries represented by Cell J of Table 1. Benefit months are months during which beneficiaries had pharmacy benefit coverage.
b. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability

or blindness. The children's group includes children receiving foster care and adoptive services. The total includes some beneficiaries with unknown basis of eligibility and some whose age categories

are not consistent with basis of eligibility.

c. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; FFS = fee-for-service pharmacy benefit; MAX = Medicaid Analytic Extract; MC = managed care; Rx = pharmacy benefit.

#### APPENDIX TABLE A.2

### MEDICAID BENEFICIARIES AND THEIR BENEFIT MONTHS WITH OR WITHOUT FEE-FOR-SERVICE PHARMACY BENEFITS<sup>a</sup> NONDUAL BENEFICIARIES, TEXAS, 2005

Beneficiaries and Benefit Months in Cell J of Table 1 Included in Cell K of Table 1 Excluded from Cell K of Table 1 Number of Number of Number of Number of Number of Number of Beneficiaries Benefit Months Beneficiaries Benefit Months Beneficiaries Benefit Months ΑII 5,864,602 3,425,751 29,704,067 3,253,138 23,839,465 Fee-for-service (FFS) all year 168 2,067,771 17,566,297 2,067,771 17,566,129 0 FFS part year, with Rx claims 532,640 5,051,074 532,640 1,545,023 0 3,506,051 FFS part year, with no Rx claims 239,823 1,905,975 239,823 675,401 0 1,230,574 Managed care (MC) all year, with Rx claims 412,904 4,052,912 412,904 4,052,912 0 0 0 MC all year, with no Rx claims 172,599 1,127,719 0 0 1,127,719

Source: Data for this table are from the MAX 2005 file for Texas, released by CMS in 10/2008. This table was produced on 04/23/2009.

a. Benefit months are months during which beneficiaries had pharmacy benefit coverage.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; FFS = fee-for-service pharmacy benefit; MAX = Medicaid Analytic Extract; MC = managed care; Rx = pharmacy benefit.